Unresectable Hepatocellular Carcinoma
Also known as: Unresectable Hepatocellular Carcinoma (HCC)
Drug | Drug Name | Drug Description |
---|---|---|
DB11595 | Atezolizumab | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. |
DB11714 | Durvalumab | An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. |
DB09078 | Lenvatinib | A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. |
DB00398 | Sorafenib | A kinase inhibitor used to treat unresectable liver carcinoma, advanced renal carcinoma, and differentiated thyroid carcinoma. |
DB11771 | Tremelimumab | An anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab. |